Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Significant Decline in Short Interest

Posted by Geri Gentry on Sep 1st, 2026

Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 42,034 shares, a drop of 35.9% from the July 30th total of 65,538 shares. Based on an average daily trading volume, of 28,832 shares, the short-interest ratio is presently 1.5 days. Approximately 0.8% of the shares of the company are short sold.

Neuphoria Therapeutics Stock Up 0.4%

NEUP traded up $0.01 during trading hours on Tuesday, hitting $3.77. The stock had a trading volume of 9,516 shares, compared to its average volume of 103,963. Neuphoria Therapeutics has a 1 year low of $3.19 and a 1 year high of $21.40. The company’s fifty day simple moving average is $3.80 and its 200 day simple moving average is $4.36. The stock has a market cap of $20.38 million, a PE ratio of -0.34 and a beta of 0.75.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. HC Wainwright cut shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday. Finally, Wall Street Zen raised shares of Neuphoria Therapeutics to a “hold” rating in a report on Saturday, July 25th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $21.00.

View Our Latest Analysis on Neuphoria Therapeutics

Hedge Funds Weigh In On Neuphoria Therapeutics

Large investors have recently modified their holdings of the business. ADAR1 Capital Management LLC bought a new stake in shares of Neuphoria Therapeutics in the second quarter valued at approximately $131,000. Merck & Co. Inc. bought a new position in Neuphoria Therapeutics in the 2nd quarter worth approximately $43,818. AdvisorShares Investments LLC boosted its holdings in Neuphoria Therapeutics by 15.8% in the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock worth $632,000 after buying an additional 21,173 shares during the period. XTX Topco Ltd purchased a new position in Neuphoria Therapeutics in the 4th quarter valued at approximately $47,000. Finally, Ikarian Capital LLC purchased a new position in Neuphoria Therapeutics in the 4th quarter valued at approximately $184,000. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

(Get Free Report)

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.